MergerAug 12, 2026, 04:48 PM
CRAC Details Carvix Merger Agreement; Q2 Net Income $1.35M
AI Summary
Crown Reserve Acquisition Corp. I (CRAC) filed its Q2 2026 10-Q, detailing its Business Combination Agreement with Carvix, Inc. The merger involves Carvix stockholders receiving 50,000,001 shares of CRAC common stock upfront, plus potential earnout shares based on future EBITDA and revenue targets. The company reported a net income of $1.35 million for the three months ended June 30, 2026, but also noted a "going concern" risk if the business combination is not completed by February 10, 2027.
Key Highlights
- Entered Business Combination Agreement with Carvix, Inc. on March 30, 2026.
- Carvix stockholders to receive 50,000,001 CRAC shares at merger close.
- Contingent earnout of up to 50,000,100 shares based on 4-year EBITDA/revenue targets.
- Trust Account balance reached $176.48 million as of June 30, 2026.
- Net income for Q2 2026 was $1.35 million, up from $53 in Q2 2025.
- Net income per Class A ordinary share was $0.06 for Q2 2026.
- Warrant liability increased to $3.14 million from $1.42 million at Dec 31, 2025.
- Management identified substantial doubt about going concern if merger not completed by Feb 10, 2027.
Price Impact